Literature DB >> 11724293

Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.

C Gu1, T Oyama, T Osaki, K Kohno, K Yasumoto.   

Abstract

Y box-binding protein-1 (YB-1), a member of the DNA binding protein family, interacts with inverted CCAAT boxes (Y-boxes). Y-boxes are located on the promoter of numerous genes, such as DNA topoisomerase IIalpha (Topo IIalpha), proliferating cell nuclear antigen (PCNA) and multidrug resistance 1 (MDR1). In this study, we used immunohistochemical (IHC) staining to detect YB-1 expression in 59 lung cancer tissues and to evaluate whether YB-1 expression was associated with the expression of YB-1 target genes such as Topo IIalpha, PCNA and MDR1 in human lung carcinoma. Twenty-eight out of 59 cases (47.5%) were stained positive for YB-1 in the cytoplasm, while 30 out of 59 cases (50.8%) were positive for PCNA in the nuclei. Topo IIalpha-positive cells were detected in 16 out of 59 cases (27.1%). Eight out of 59 cases (13.6%) had greater than 5% P-gp positive cells expression. There was a significant correlation between the YB-1 and Topo IIalpha expression in small cell lung cancer (SCLC) (p=0.0242). YB-1 expression also correlated with PCNA expression in non-small cell lung cancer (NSCLC) (p=0.0001). Higher levels of YB-1 expression were associated with T3-4 and Stage III-IV tumors in adenocarcinomas (p=0.0072; p=0.0168). In contrast, no relationship was found between YB-1 expression and P-gp expression. Our study suggests that YB-1 expression correlates with Topo IIalpha and PCNA expression in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724293

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  21 in total

1.  Impact of lymph node micrometastasis in hilar bile duct carcinoma patients.

Authors:  Kentaro Taniguchi; Taku Iida; Tomohide Hori; Shintaro Yagi; Hiroshi Imai; Taizo Shiraishi; Shinji Uemoto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy.

Authors:  Y Zhang; S R Reng; L Wang; L Lu; Z H Zhao; Z K Zhang; X D Feng; X D Ding; J Wang; G Feng; T Z Dai; J Pu; X B Du
Journal:  Med Oncol       Date:  2011-09-11       Impact factor: 3.064

3.  Identification of candidate lung cancer susceptibility genes in mouse using oligonucleotide arrays.

Authors:  W J Lemon; H Bernert; H Sun; Y Wang; M You
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

4.  The N-terminal domain of y-box binding protein-1 induces cell cycle arrest in g2/m phase by binding to cyclin d1.

Authors:  Payal Khandelwal; Mythili K Padala; John Cox; Ramareddy V Guntaka
Journal:  Int J Cell Biol       Date:  2010-04-14

5.  Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Authors:  Jennifer H Law; Yvonne Li; Karen To; Michelle Wang; Arezoo Astanehe; Karen Lambie; Jaspreet Dhillon; Steven J M Jones; Martin E Gleave; Connie J Eaves; Sandra E Dunn
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

6.  Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA.

Authors:  Tony Sourisseau; Anastasios Georgiadis; Anna Tsapara; Robin R Ali; Richard Pestell; Karl Matter; Maria S Balda
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

7.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Authors:  Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe P Roux; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-11-27       Impact factor: 6.466

8.  Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

Authors:  Edgar Dahl; Abdelaziz En-Nia; Frank Wiesmann; Renate Krings; Sonja Djudjaj; Elisabeth Breuer; Thomas Fuchs; Peter J Wild; Arndt Hartmann; Sandra E Dunn; Peter R Mertens
Journal:  BMC Cancer       Date:  2009-11-24       Impact factor: 4.430

9.  YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression.

Authors:  Joyce Wu; Anna L Stratford; Arezoo Astanehe; Sandra E Dunn
Journal:  Transl Oncogenomics       Date:  2007-05-11

Review 10.  A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance.

Authors:  Akram Alkrekshi; Wei Wang; Priyanka Shailendra Rana; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Cell Signal       Date:  2021-07-03       Impact factor: 4.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.